Novel Antimalarial Drug Targets
Closed Special Notice Posted
- Solicitation number
- PANDHA-25-P-0000-015601_NOI_Sole_Source
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- United States
Notice details come from SAM.gov. Updated .
About this opportunity
The United States Army Medical Research Acquisition Activity (USAMRAA), under the Defense Health Agency, has issued a Special Notice for a sole source contract with Portland State University (PSU). The notice pertains to a research opportunity focused on investigating novel antimalarial drug targets through affinity-based pulldowns. This contract is being negotiated in accordance with Federal Acquisition Regulation (FAR) 13.5, which allows for direct negotiation with a specific contractor. The opportunity is related to work for the Walter Reed Army Institute of Research (WRAIR), specifically the Center for Infectious Disease Research's Viral Diseases Branch. The special notice was posted on May 22, 2025, with a response deadline of June 2, 2025.
The primary objective of this research contract is to support advanced antimalarial drug development through comprehensive chemical and biological testing. PSU is identified as the sole responsible source capable of conducting the required research, which includes developing chemistry expertise for compound WR936909's Structure-Activity Relationship (SAR). The contractor will be responsible for producing chemical probes and performing activity-based protein profiling, with specific research milestones involving testing compounds in Plasmodium asexual blood-stage assays and subsequently moving promising compounds into Plasmodium liver-stage models. The contract falls under the NAICS category of Research and Development in Biotechnology (541714) and the PSC category of Health R&D Services. Eligibility is limited to Portland State University, as they are deemed the only institution capable of meeting the specialized research requirements for this critical antimalarial drug target investigation.
Notice text
Place of Performance: Contractor Facility
The United States Army Medical Research Acquisition Activity (USAMRAA) intends to negotiate on a sole source basis IAW FAR 13.5 to Portland State University (PSU) 1600 SW 4th Ave. Portland, OR 97201 as the only responsible source that can provide Walter Reed Army institute of Research (WRAIR), Center for Infectious Disease Research (CIDR), Viral Diseases Branch (VDB) to support the investigation of Novel Antimalarial Drug Targets through affinity-based pulldowns. Research efforts shall require chemistry expertise in compound WR936909 Structure-Activity Relationship (SAR) in order to produce probes and activity-based protein profiling. As well collaborator must be able to first test compounds and chemical probes in the Plasmodium asexual blood-stage assay before compounds and chemical probes are moved into the Plasmodium liver-stage model.
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Special Notice | |
| RFI Novel Antimalarial Drug Targets | Pre-Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity